Vitalus Health will bring Adherium’s Hailie solution to more than 40,000 affected lives in the Vitalus Health provider system.
Designed for patients with asthma and COPD, the Hailie solution consists of a sensor that attaches to a patient’s asthma or COPD inhaler medication and software, including an app and online web portal, for both patients and clinicians.
The sensor tracks medication usage and sends reminders to patients when it is time to take their medication, helping them to monitor and promote adherence as part of self-management plan. The collected data can be reviewed by patients, clinicians, parents and other caregivers.
On July 26, 2018, Adherium announced the U.S. Food and Drug Administration granted 510(k) clearance for over-the-counter sales of its Hailie sensor for use with ProAir HFA, Ventolin HFA, and Flovent HFA asthma inhalers, adding to the clearance previously received for the Hailie sensor for use with Symbicort.
“We are delighted to broaden our relationship with Vitalus Health. Since joining forces earlier this year, we’ve seen a clear path towards a stronger relationship and the potential for better patient outcomes,” said Arik Anderson, CEO of Adherium. “We are confident that our Hailie solution will provide further support to Vitalus Health’s efforts to achieve impactful results throughout the patient-care spectrum while reducing healthcare costs. Our shared objective to improve not only the healthcare system but also the patient experience, makes this strategic partnership a natural fit. This further signals Adherium’s growing commercial presence in the US. Our software platform is built for scalability, and Vitalus Health is the ideal partner to grow with.”
